GNBT Projected Dividend Yield

Com Par $0.001/Generex Biotechnology Corp (DE) ( OTCBB : GNBT )

Generex Biotechnology is a healthcare holding company. Through its subsidiaries, Co. provides end-to-end solutions for physicians and patients. Co.'s majority-owned subsidiary, Olaregen Therapeutix, Inc. (Olaregan), is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the wound care market. Olaregen's product, Excellagen® (wound conforming matrix) is a topically applied product for dermal wounds and other indications. Co.'s majority-owned subsidiary, Regentys Corporation, is a regenerative medicine company developing a tissue engineered therapy for the treatment of ulcerative colitis.

21 YEAR PERFORMANCE RESULTS